Clinical Trials for Alife

Explore 10 clinical trials worldwide

Showing 1-10 of 10 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Alife

Clinical Trials (10)

NCT07157956
CVL006 Combination Therapy in Advanced Solid Tumors
PHASE1/PHASE2Not yet recruiting
318 participants
Started: Sep 10, 2025 · Completed: Dec 30, 2028
1 condition1 sponsor1 location
NCT06621615
Clinical Study of CVL006 Injection in Advanced Solid Tumors
PHASE1Not yet recruiting
120 participants
Started: Nov 20, 2024 · Completed: Nov 20, 2028
1 condition1 sponsor0 locations
NCT06519110
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
PHASE2Not yet recruiting
60 participants
Started: Aug 10, 2024 · Completed: Apr 15, 2026
1 condition1 sponsor0 locations
NCT06374888
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
PHASE2Not yet recruiting
28 participants
Started: Apr 30, 2024 · Completed: Jul 30, 2027
1 condition1 sponsor0 locations
NCT06610123
Caffeine, CYPA12 and Resistance Training
NARecruiting
48 participants
Started: Apr 1, 2024 · Completed: Jul 30, 2025
2 conditions3 sponsors1 location
NCT06610110
Caffeine, CYPA12 and Resistance Exercise
NARecruiting
60 participants
Started: Apr 1, 2024 · Completed: Jul 30, 2025
2 conditions3 sponsors2 locations
NCT06293716
CVL237 Tablets for APDS/PASLI
PHASE2/PHASE3Not yet recruiting
35 participants
Started: Mar 30, 2024 · Completed: Mar 30, 2026
1 condition1 sponsor1 location
NCT06183736
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
PHASE2Not yet recruiting
98 participants
Started: Dec 20, 2023 · Completed: Jun 30, 2027
1 condition1 sponsor1 location
NCT06029816
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
PHASE2Not yet recruiting
42 participants
Started: Nov 20, 2023 · Completed: Dec 30, 2025
1 condition1 sponsor1 location
NCT05483985
Evaluation of the Alife Hera System as an Adjunctive Tool for the Prioritization of Embryos Deemed Suitable for Transfer
NAActive, not recruiting
440 participants
Started: Jun 13, 2022 · Completed: Jan 31, 2025
1 condition1 sponsor7 locations